Malaria:
Indications for: PRIMAQUINE
For the radical cure (prevention of relapse) of vivax malaria.
Adult Dosage:
1 tab daily for 14 days.
Children Dosage:
Not recommended.
PRIMAQUINE Contraindications:
Severe G6PD deficiency. Acutely ill patients suffering from systemic disease manifested by tendency to granulocytopenia (eg, rheumatoid arthritis, SLE). Concomitant hemolytic or bone marrow suppressive drugs, quinacrine. Pregnancy.
PRIMAQUINE Warnings/Precautions:
Perform G6PD testing prior to initiation. Mild-to-moderate G6PD deficiency or unknown G6PD status: assess risk vs. benefit; if considered, monitor hbg/hct at baseline, at Days 3 and 8 of therapy; have medical support available. Discontinue if signs of hemolytic anemia occur. History of favism. Perform routine CBCs during therapy; in those with history of hemolytic anemia or nicotinamide adenine dinucleotide (NADH) methemoglobin reductase deficiency; monitor closely. Risk for QT prolongation in cardiac disease, long QT syndrome, history of ventricular arrhythmias, uncorrected hypokalemia and/or hypomagnesemia, or bradycardia (<50bpm); monitor ECG. Elderly. Females of reproductive potential should exclude pregnancy prior to initiation and use effective contraception during and after stopping treatment until completion of on-going ovulatory cycle; males should use condoms during and for 3 months after therapy. Nursing mothers: not recommended.
PRIMAQUINE Classification:
Aminoquinoline.
PRIMAQUINE Interactions:
See Contraindications. Caution with concomitant other drugs that prolong the QT interval.
Adverse Reactions:
Nausea, vomiting, epigastric distress, abdominal cramps, leukopenia, cardiac arrhythmia, dizziness, rash, pruritus.
How Supplied:
Tabs—100
